Clinical trial expansion in the US, in collaboration with the University of Iowa, to treat high-risk, resistant, non-muscle-invasive bladder cancer (NMIBC)

LUND, Sweden, June 22, 2026 /PRNewswire/ — Hamlet BioPharma AB (publ) today announced the signing of a clinical trial agreement with the University of Iowa, one of the leading U.S. centers for bladder cancer research and therapy. The…

Read the full release →

News provided by PR Newswire.